Earnings Results: ‘This will likely end badly’: Analysts react to Mylan’s revenue miss and earnings call

Shares of Mylan N.V. plunged 21% on Wednesday, as the stock headed toward its steepest one-day decline in 19 years.

The slide came after the EpiPen maker MYL, -21.99%reported revenue that missed Wall Street expectations for the third time in the past four quarters, yet did not provide anxious and impatient investors with any update on its plan to turn things around at the company.

Mylan’s board said in August that it would form a committee to conduct a strategic review to look at “a wide range of alternatives to unlock the true value of our one-of-a-kind platform.

>>> Original Source <<<